Related Experiment Video
Updated: Jul 8, 2026
05:23
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
Enhanced H. pylori Treatment Using a β-Cyclodextrin-Propolis Complex: A Randomized Clinical Trial
Aisa Mehri1, Shabnam Pourmoslemi1, Alireza Khalilian2
1Department of Pharmaceutics, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran, umsha.ac.ir.
Biomed Research International
|July 7, 2026
Summary
A novel beta-cyclodextrin-propolis complex shows promise as a natural adjunctive therapy for Helicobacter pylori infection, improving eradication rates and symptom relief with minimal side effects.
Area of Science:
- Natural Product Chemistry
- Clinical Microbiology
- Pharmacology
Background:
- Helicobacter pylori infection presents a significant global health challenge, exacerbated by antibiotic resistance and treatment side effects.
- Propolis, a natural resin, possesses antimicrobial and anti-inflammatory properties but is limited by poor solubility and bioavailability.
- A beta-cyclodextrin-propolis complex was developed to enhance propolis delivery and efficacy for H. pylori infections.
Purpose of the Study:
- To evaluate the therapeutic efficacy of a beta-cyclodextrin-propolis complex as an adjunct to standard quadruple therapy for H. pylori eradication.
- To assess the impact of the complex on gastrointestinal symptom resolution and patient outcomes.
- To characterize the physical and release properties of the beta-cyclodextrin-propolis complex.
Main Methods:
- A double-blind, randomized clinical trial involving biopsy-confirmed H. pylori patients.
- Participants received standard quadruple therapy with omeprazole, plus either the beta-cyclodextrin-propolis complex (250 mg/day) or placebo for 2 months.
- Outcomes were measured via fecal antigen tests and symptom questionnaires; complex characterization included FESEM, FTIR, and drug release studies.
Main Results:
- The beta-cyclodextrin-propolis complex exhibited successful formation and sustained propolis release.
- A higher proportion of patients receiving the complex achieved negative H. pylori antigen tests and symptom resolution (57.1%) compared to placebo (41.6%).
- Adverse effects were mild and comparable between the treatment and control groups.
Conclusions:
- The beta-cyclodextrin-propolis complex demonstrates potential as an effective natural adjunct for H. pylori treatment.
- This complex may improve eradication rates and alleviate gastrointestinal symptoms associated with H. pylori infection.
- Further research into natural adjuncts like this complex is warranted given rising antibiotic resistance.
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:26Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:26Gastritis II: Pathophysiology
The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
01:23Gastritis III: Clinical Manifestations and Management
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...